Wollenberg A, Beck LA, Blauvelt A, et al. - Given that dupilumab (monoclonal antibody blocking the shared receptor subunit for IL-4 and IL-13) trials of up to 52 weeks showed the effectiveness and a favourable safety profile in patients with moderate-to-severe atopic dermatitis (AD) inadequately controlled with topical medications, researchers further described the safety of dupilumab by assessing clinical laboratory findings from three randomised, double-blinded, placebo-controlled phase III trials (LIBERTY AD SOLO 1 & 2 and LIBERTY AD CHRONOS). Patients were randomised to dupilumab weekly, every 2 weeks or placebo at 1:1:1 (SOLO 1 & 2) or 3:1:3 (CHRONOS) for 16 and 52 weeks, respectively. Laboratory results were reviewed descriptively in 1,376 individuals from SOLO 1 & 2 and 740 from CHRONOS. No clinically important changes were found in routine laboratory parameters that could be attributed to dupilumab. In dupilumab vs placebo groups, platelets and neutrophils displayed mild decreases from baseline. Grade 3 eosinophilia has been reported in < 1% of dupilumab-treated and placebo-treated patients. Eosinophilia was not correlated with any adverse events. This research promotes the use of dupilumab as a systemic therapy that does not involve laboratory supervision for moderate-to-severe AD.